3-substituted benzamide derivatives could be used to treat chronic myeloid leukemia (CML)

07-24-2006

According to recent research published in the journal Bioorganic & Medicinal Chemistry Letters, "A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat CML, was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562."

"About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors," explained T. Asaki and colleagues, Nippon Shinyaku Co.

The researchers concluded, "One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia."

Asaki and colleagues published their study in Bioorganic & Medicinal Chemistry Letters (Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett, 2006;16(5):1421-1425).

For additional information, contact T. Asaki, Nippon Shinyaku Co. Ltd, Discovery Research Laboratories, Minami Ku, 14 Nishinosho Monguchi Cho, Kyoto 6018550, Japan.

Keywords: Kyoto, Japan, Antiproliferative Activity, Bcr Abl, Chronic Myeloid Leukemia, Imatinib, Inhibitor, Oncology, Proteins, Proteomics, Structure Activity, Cancer Therapy, Tyrosine Kinase.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.